A startup company founded by Oxford University professors is making waves in the stem cell community because it has technology that promises to control in vivo the destination of cells that can repair and replace tissues affected by disease. The technology will be used to create small molecule drugs that can activate repair mechanisms that already exist in the body to treat major age-related diseases such as cancer, neurodegeneration, heart failure and macular degeneration.
